Zymeworks Inc. (ZYME)
NASDAQ: ZYME · IEX Real-Time Price · USD
9.78
-0.03 (-0.31%)
At close: Jul 19, 2024, 4:00 PM
9.55
-0.23 (-2.35%)
Pre-market: Jul 22, 2024, 7:32 AM EDT
Zymeworks Revenue
Zymeworks had revenue of $50.46M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $10.03M. In the year 2023, Zymeworks had annual revenue of $76.01M.
Revenue (ttm)
$50.46M
Revenue Growth
-88.69%
P/S Ratio
13.70
Revenue / Employee
$181,525
Employees
278
Market Cap
691.49M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
Dec 31, 2014 | 1.67M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Paragon 28 | 225.44M |
Weave Communications | 178.08M |
SIGA Technologies | 157.02M |
SI-BONE | 144.05M |
Arbutus Biopharma | 12.99M |
Stoke Therapeutics | 7.85M |
ZYME News
- 2 hours ago - Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate - GlobeNewsWire
- 11 days ago - Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 - GlobeNewsWire
- 5 weeks ago - Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers - GlobeNewsWire
- 6 weeks ago - Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer - GlobeNewsWire
- 7 weeks ago - Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME - Accesswire
- 7 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME - Accesswire
- 2 months ago - Lost Money on Zymeworks Inc.(ZYME)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Accesswire